Health Logic subsidiary appoints New to advisory board

Mr. George Kovalyov reports


Health Logic Interactive Inc.’s wholly owned operating subsidiary, My Health Logic Inc., has hired Dr. Marta New as a strategic advisor to the company. Dr. New will be instrumental in the company’s development as it continues its search for online digital health platforms and digitally connected medical devices.

Dr. New is founder and chief executive officer of Radyus Research, a highly regarded contract research organization focused on preclinical drug development services combined with comprehensive scientific and strategic consulting. Dr. New was co-founding partner at Agent Capital, participating in multiple venture capital investments including Orchard Therapeutics and Precision Biosciences, among others. Dr. New began her investment career at Baxter Ventures, focusing on medical devices, diagnostics and therapeutic investments strategic to Baxter, including chronic kidney disease. She also spent several years at Baxter’s global renal marketing franchise, where she was the commercial lead for multiple new CKD products being launched in the United States and international markets.

“We are very excited to have Dr. New as a part of our team, her strong experience in successfully financing and commercializing medical devices and diagnostics will be of significant value as our company continues to grow,” said David Barthel, CEO.

About the company

Health Logic Interactive plans to develop and commercialize novel technologies through its wholly owned operating subsidiary, My Health Logic. At the present time, the company is not engaged in active business operations. The company intends to acquire and commercialize consumer focused health care technologies that address areas of unmet needs. However, to date it has not entered into any binding agreements for such acquisitions and there can be no guarantee that the company will be able to successfully identify, negotiate and complete such acquisitions, or raise the necessary finances for such acquisitions or for the development of its business should it be able to complete such acquisitions.

© 2021 Canjex Publishing Ltd. All rights reserved.